title: Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid.
abstract: Treatment of differentiated thyroid cancer is a success of modern medicine with the use of radioiodine ((131)I). However, a significant proportion of thyroid cancers may be non-iodine avid. Thyroid tumours are known to express somatostatin receptors. Octreotide, an analogue of somatostatin, can be combined with a radioactive isotope, such as (111)In-DTPA(0) to visualise tumours with high concentrations of somatostatin receptors. We assessed 18 patients with histologically proven metastatic or locally recurrent non-iodine avid thyroid carcinoma to determine the usefulness of (111)In-DTPA(0) octreotide scintigraphy compared to conventional radiology in diagnosing sites of metastasis. The diagnosis of metastatic disease was made using conventional radiology and all had prospective scintigraphy using (111)In-DTPA(0)octreotide. Of the 18 patients, 14 had octreotide-positive scans. In eight, the octreotide scans identified the same sites of metastases as conventional radiology, that is, were concordant. In nine patients, conventional radiology showed more extensive disease than revealed on the octreotide scans. In one patient with widespread bone metastases, octreotide gave a more detailed assessment of metastatic disease than conventional radiology. These data indicate that (111)In-DTPA(0)octreotide imaging for patients with non-iodine avid carcinoma of the thyroid may be a useful diagnostic and staging tool. One patient with Hurthle cell carcinoma metastatic to bone and a positive octreotide scan has been treated with (90)yttrium-labelled octreotide.
authors.affiliation: Thyroid Unit, Royal Marsden Hospital, Surrey, UK. j.christian@cr.ac.uk
authors.forename: J A
authors.initials: JA
authors.lastname: Christian
authors.forename: G J R
authors.initials: GJ
authors.lastname: Cook
authors.forename: C
authors.initials: C
authors.lastname: Harmer
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D002614:Chelating Agents; D006801:Humans; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging*; D009367:Neoplasm Staging / Q000379:methods*; D015282:Octreotide / Q000008:administration & dosage* / Q000494:pharmacology*; D004369:Pentetic Acid; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000187:drug effects / Q000502:physiology; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D002614:Chelating Agents; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D017481:Receptors, Somatostatin; D004369:Pentetic Acid; D015282:Octreotide